Whereas nivolumab in combination with ipilimumab or platinum‐ and fluoropyrimidine‐based chemotherapy is approved for the first‐line treatment of unresectable advanced or metastatic ESCC in the United States, and in Europe in patients with tumor cell PD‐L1 expression ≥1%.19, 20. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.